Your session is about to expire
← Back to Search
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET Scan for Cancer
Study Summary
This trial uses a radioactive antibody to help detect cancer cells in patients with high levels of a protein called CEA. PET scans may help find and diagnose cancer that may not be detected by other methods.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had allergic reactions to similar drugs or substances as 64Cu-M5A.I am not pregnant and will stop breastfeeding if treated with 54Cu-m5A.I do not have any uncontrolled illnesses or active infections.I haven't had chemotherapy or radiation in the last 2 weeks.I have recent (within 2 months) CT scans and blood tests.I can understand and am willing to sign the consent form.I have been exposed to certain mouse or human/mouse antibodies and have developed an antibody response.I finished any cancer treatments like chemotherapy or radiotherapy at least 2 weeks ago.My tumor produces CEA, or I have colorectal cancer.I had a detectable cancer site before starting treatment and may now be in remission.My cancer type was confirmed by a biopsy and reviewed by City of Hope's Pathology Department.
- Group 1: Diagnostic (copper Cu 64 anti-CEA monoclonal antibody M5A PET)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there other investigations concerning the effects of Cu 64 anti-CEA monoclonal antibody M5A IV?
"Presently, seven clinical trials utilizing Cu 64 anti-CEA monoclonal antibody M5A IV are underway with one at Phase 3. With the majority of studies taking place in Saint Louis, Missouri, a total of 16 sites have been identified to handle these investigations."
For what afflictions has Cu 64 anti-CEA monoclonal antibody M5A IV proven to be beneficial?
"Copper-64 anti-CEA monoclonal antibody M5A IV can be utilized to manage trace element deficiencies, an individual's weight exceeding 40 kilograms, as well as Intrauterine Device (IUD) therapy."
Are there still opportunities to join this scientific investigation?
"Sadly, this medical trial has concluded its patient recruitment phase. It was initially posted on the 11th of November 2015 and had its last update on October 20th 2022. However, other trials that may interest you include 5126 studies for cancer of the gallbladder and 7 clinical investigations related to Cu 64 anti-CEA monoclonal antibody M5A IV actively seeking participants."
What is the cap on enrolment for this clinical trial?
"This study is not presently accepting participants. It was first posted in November of 2015 and the latest update occurred on October 20th, 2022. Alternately, right now there are 5126 trials that require gallbladder cancer patients and seven studies seeking enrolment for Cu 64 anti-CEA monoclonal antibody M5A IV."
Share this study with friends
Copy Link
Messenger